Adagio Medical Holdings sets date for 2025 annual meeting and proposal deadlines

Adagio Medical Holdings, Inc. (NASDAQ:ADGM) announced Thursday that its board of directors has scheduled the company’s 2025 annual meeting of stockholders for December 15, 2025. The company stated in a press release via a U.S. Securities and Exchange Commission filing that the time and location of the meeting will be detailed in its forthcoming proxy statement.

The record date for determining stockholders entitled to receive notice of and vote at the annual meeting is set for the close of business on October 31, 2025.

Adagio Medical Holdings noted that it did not hold a 2024 annual meeting. As a result, the company is providing advance notice to stockholders regarding the deadlines for submitting qualified proposals and director nominations for inclusion in the proxy materials for the 2025 meeting.

Stockholders who wish to submit proposals under Exchange Act Rule 14a-8 for inclusion in the proxy materials must ensure that their proposals are delivered to or received by the company’s Secretary at its Laguna Hills, California office no later than November 3, 2025. The same deadline applies for stockholder director nominations and other proposals to be considered at the meeting, in accordance with the company’s amended and restated bylaws.

In addition, stockholders intending to solicit proxies in support of director nominees other than the company’s nominees must provide notice with the required information under Rule 14a-19 of the Exchange Act by November 3, 2025.

The company said all submissions must comply with applicable SEC rules and the company’s bylaws. Details regarding the meeting’s time and location will be included in the definitive proxy statement to be filed with the SEC.

This information is based on a press release statement contained in the company’s recent SEC filing.

In other recent news, Adagio Medical Holdings, Inc. has closed a $50 million private placement, primarily supported by existing and new healthcare-focused institutional investors. The funds are earmarked for FDA submission activities related to its vCLAS™ ULTC System and to enhance manufacturing capabilities. Additionally, Adagio Medical announced a separate securities purchase agreement, raising $19 million upfront, with potential for an additional $31 million if warrants are exercised. This transaction is led by Perceptive Advisors, LLC, alongside other healthcare-dedicated investors. In clinical developments, Adagio reported a 97.4% acute clinical success rate for its Ultralow Temperature Cryoablation system in a ventricular tachycardia study involving 207 patients. The company also completed enrollment of 208 patients in its FULCRUM-VT pivotal study across 20 centers in the United States and Canada. Furthermore, Adagio is set to present acute results from its FULCRUM-VT study at the 20th Annual International Symposium on Ventricular Arrhythmias in Philadelphia.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.